PARD6G

Across TCGA pan-cancer cohorts, PARD6G mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARD6G data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PARD6G mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PARD6G expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where PARD6G mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.362	0.704	<.001	38	view →
LSCC	OS	Quartile	II,III,IV	0.926	0.607	.026	6	view →
LUAD	DFS	Quartile	II,III,IV	0.360	0.709	.034	6	view →
UCEC	OS	Tertile	II,III,IV	0.597	1.000	.037	4	view →
CCRCC	DFS	Tertile	All	0.880	0.586	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARD6G–PDAC (OS)

Open the PDAC breakdown →